share_log

Returns On Capital At Surgery Partners (NASDAQ:SGRY) Have Hit The Brakes

Returns On Capital At Surgery Partners (NASDAQ:SGRY) Have Hit The Brakes

Surgery Partners(納斯達克股票代碼:SGRY)的資本回報率已經停滯不前
Simply Wall St ·  03/27 06:30

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. However, after briefly looking over the numbers, we don't think Surgery Partners (NASDAQ:SGRY) has the makings of a multi-bagger going forward, but let's have a look at why that may be.

我們應該尋找哪些趨勢?我們想確定可以長期價值成倍增長的股票?理想情況下,企業將表現出兩種趨勢;首先是增長 返回 論資本使用率(ROCE),其次是增加 金額 所用資本的比例。這向我們表明,它是一臺複合機器,能夠持續將其收益再投資到業務中併產生更高的回報。但是,在簡短地研究了這些數字之後,我們認爲Surgery Partners(納斯達克股票代碼:SGRY)在未來不具備多袋裝機的實力,但讓我們來看看爲什麼會這樣。

Understanding Return On Capital Employed (ROCE)

了解資本使用回報率 (ROCE)

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. Analysts use this formula to calculate it for Surgery Partners:

如果你以前沒有與ROCE合作過,它會衡量公司從其業務中使用的資本中產生的 “回報”(稅前利潤)。分析師使用以下公式來計算手術合作伙伴的利潤:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

已動用資本回報率 = 息稅前收益 (EBIT) ¥(總資產-流動負債)

0.065 = US$415m ÷ (US$6.9b - US$523m) (Based on the trailing twelve months to December 2023).

0.065 = 4.15億美元 ÷(69億美元-5.23億美元) (基於截至2023年12月的過去十二個月)

Therefore, Surgery Partners has an ROCE of 6.5%. Ultimately, that's a low return and it under-performs the Healthcare industry average of 11%.

因此,Surgery Partners的投資回報率爲6.5%。歸根結底,這是一個低迴報,其表現低於醫療保健行業11%的平均水平。

roce
NasdaqGS:SGRY Return on Capital Employed March 27th 2024
納斯達克GS:SGRY 2024年3月27日動用資本回報率

Above you can see how the current ROCE for Surgery Partners compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering Surgery Partners for free.

上面你可以看到Surgery Partners當前的投資回報率與其先前的資本回報率相比如何,但從過去可以看出來的只有那麼多。如果你願意,你可以免費查看涵蓋外科合作伙伴的分析師的預測。

So How Is Surgery Partners' ROCE Trending?

那麼手術夥伴的投資回報率趨勢如何呢?

In terms of Surgery Partners' historical ROCE trend, it doesn't exactly demand attention. The company has employed 47% more capital in the last five years, and the returns on that capital have remained stable at 6.5%. Given the company has increased the amount of capital employed, it appears the investments that have been made simply don't provide a high return on capital.

就Surgery Partners的歷史投資回報率趨勢而言,這並不完全值得關注。在過去五年中,該公司僱用的資本增加了47%,該資本的回報率一直穩定在6.5%。鑑於該公司增加了動用資本金額,看來已經進行的投資根本無法提供很高的資本回報率。

The Bottom Line

底線

As we've seen above, Surgery Partners' returns on capital haven't increased but it is reinvesting in the business. Investors must think there's better things to come because the stock has knocked it out of the park, delivering a 146% gain to shareholders who have held over the last five years. Ultimately, if the underlying trends persist, we wouldn't hold our breath on it being a multi-bagger going forward.

正如我們在上面看到的那樣,Surgery Partners的資本回報率沒有增加,但它正在對業務進行再投資。投資者一定認爲會有更好的事情發生,因爲該股已經脫穎而出,爲在過去五年中持股的股東帶來了146%的收益。歸根結底,如果潛在的趨勢持續下去,我們就不會屏住呼吸了,因爲它是未來的 “多管齊下”。

On a separate note, we've found 1 warning sign for Surgery Partners you'll probably want to know about.

另一方面,我們爲你可能想知道的手術夥伴找到了一個警告標誌。

While Surgery Partners isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

儘管Surgery Partners的回報率並不高,但請查看這份免費清單,列出了資產負債表穩健的股本回報率高的公司。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論